Why did we invest?
Pioneering approach
Igyxos Biotherapeutics stood out for its pioneering approach to tackling infertility—a growing global crisis affecting 1 in 6 couples. With its lead asset, IGX12, Igyxos is developing the first-ever treatment for male infertility, a condition that accounts for 50% of fertility issues yet remains underdiagnosed and untreated. By enhancing the bioactivity of FSH, IGX12 offers a transformative solution for men with oligospermia and women undergoing IVF, improving outcomes and reducing the physical and emotional burden of current treatments.
Market potential
We have been highly impressed by Igyxos’ seasoned team and its world-class Scientific Advisory Board. With a solid foundation of robust preclinical and Phase 1 clinical data, the company is well-positioned to advance IGX12 into the next phase of clinical development. The global fertility market—valued at £27 billion in 2023 and expected to nearly double by 2033—represents a significant opportunity for this first-in-class therapy. Through our partnership with Igyxos, we are proud to support a company that not only addresses a critical unmet medical need but also holds the potential to transform infertility treatment on a global scale.
Key Impact areas
Tackling a global challenge
IGX12 improves the efficacy of FSH in women undergoing IVF, increasing mature oocyte production and reducing the number of cycles needed. This advancement could lower the physical, emotional, and financial burden of fertility treatments for women classified as poor responders.
Enhancing success rates
Igyxos’ differentiated mechanism offers a novel approach after decades of stagnation in fertility treatment innovation. Its robust preclinical and phase 1 data to date and scalable development plan position IGX12 as a transformative therapy in reproductive medicine.
Innovation in fertility treatment
Igyxos are committed to supporting ground-breaking innovations that address critical unmet medical needs. With infertility rates rising globally due to factors like declining sperm counts and delayed childbearing, Igyxos addresses a critical unmet need. By targeting both male and female infertility, IGX12 offers a comprehensive solution in a market primed for rapid growth.
